Pasithea Therapeutics -CW26KTTAWPreferred / convertible
13F holders, Q1 2026 (March 31)5holders +1
1new positions
0sold out
$0.01avg. 13F price*
At the end of Q1 2026, 5 institutions reported holding Pasithea Therapeutics -CW26 (KTTAW) in their 13F filings, up 1 from Q4 2025. 1 opened new positions and 0 sold out. The largest holders were Kepos Capital LP ($4K), Armistice Capital, LLC ($565) and Two Sigma Securities, LLC ($556).
- Company
- Pasithea Therapeutics -CW26
- CUSIP
- 70261F111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $150 |
| Exits | 0 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 15,065 shares bought, net +15,065 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Kepos Capital LP | — | No change | 334,600 | $4K |
| Armistice Capital, LLC | — | No change | 50,000 | $565 |
| Two Sigma Securities, LLC | — | Add +0.1% | 55,644 | $556 |
| Marex Group Ltd | — | No change | 25,000 | $250 |
| Osaic Holdings, Inc. | — | New | 15,000 | $150 |
"% of holder's portfolio" is KTTAW's weight in each manager's 13F, not the share of Pasithea Therapeutics -CW26 the manager owns.